APA (7th ed.) Citation

TH, V., HT, T. N., TV, T., MC, T., TB, X., AT, N., . . . LK, D. (2025). Real-World Evidence for First-Line afatinib in Advanced Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations Other than G719X/L861Q/S768I. Cancer control : journal of the Moffitt Cancer Center, 32, 10732748251386133. https://doi.org/10.1177/10732748251386133

Chicago Style (17th ed.) Citation

TH, Vu, et al. "Real-World Evidence for First-Line Afatinib in Advanced Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations Other than G719X/L861Q/S768I." Cancer Control : Journal of the Moffitt Cancer Center 32 (2025): 10732748251386133. https://doi.org/10.1177/10732748251386133.

MLA (9th ed.) Citation

TH, Vu, et al. "Real-World Evidence for First-Line Afatinib in Advanced Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations Other than G719X/L861Q/S768I." Cancer Control : Journal of the Moffitt Cancer Center, vol. 32, 2025, p. 10732748251386133, https://doi.org/10.1177/10732748251386133.